Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for adult female acne
ISRCTN12892056Phase 3Completed
- Sponsor
- University of Southampton
- Start
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing Spironolactone with Placebo (2 arms). Primary endpoint: Acne-QoL symptom subscale score at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
spironolactone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ISRCTN12892056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12892056.